Our long term vision and goals

Replacing Animal Testing Through Technological Convergence

Experience a new age of drug testing

We are convinced that the technological convergence of Microfluidic Organ-On-Chip, Multi-omics, the most advanced imaging techniques and artificial intelligence will allow to better predict drugs effects on the human body and bring the possibility to replace animal testing

Most experiments on animals are not relevant to human health. This leads to very high failure rates (<95%) of drugs tested on current preclinical animal models (first evaluation of a drug candidate before clinical trial or administration to humans).

Our mission is to develop a technological platform combining microfluidic technology, artificial intelligence, and the most advanced imaging techniques allowing the scientific paradigm shift from animal to 3D In vitro toxicology and efficacy prediction.

This platform allows us to validate at an early stage (before clinical trials) the safety and efficacy of the drug under development.

Reliable and early predictions allow us to focus human resources and financial investments towards the best drug candidates. The reduction of the development cost of each new drug will permit on the investment in the drugs better able to treat rare and chronic diseases, cancer, bacterial resistance and viral pandemics.
Besides, this platform is an alternative to the animal model, which is still widely used because it is regulated, although ineffective.

Our Vision

To reduce and replace animal testing to predict drugs effects on human body, we are convinced that we can reach the full potential of drug prediction by combining Artificial Intelligence, Microfluidic instruments, Multi Omic Sensors and High-resolution live Imaging.

Our Mission

Our mission is to develop an Organ-On-Chip platform that will provide massive and high-quality biological data coming from Multi-Omic analysis & the most advanced imaging techniques. This approach has the potential to become the next standard in drug development and replace animal experimentation.

Our Unique Approach

We convert any commercial multiwell plate into a standard in vitro 3D cell culture plate by adding our microfluidic perfusion lid, to culture any tissue, organs, physiopathologic and pathologic.

Meet the team

Pierre Gaudriault, PhD Late Founder - Scientific Chief Business Developer
Chloe Porcier Chief Human Resources

Jeremy Cramer, PhD Co-Founder & CEO

Priyanka Fernandes, PhD Immunologist Project Manager

Jean-Robin Peiteado Mechatronics Project Manager

Florentine Cadot Biolab Intern
Clément Pouget-Osmont VP Marketing
Alberto Ortega R&D Manager - Product Development & Industrialization
Mathilde Cadoux, PhD Immunologist Project Manager

Dario Fassini, PhD Late Founder - CSO & Head of Preclinical Model Developement
Hang Pham Lead Acquisition & Marketing Manager
Harry Dawson, PhD Scientific Project Manager

Hadhemi Mejri Biotechnology Engineer and Lab Manager
Mehdi Faraj Purchase, Logistic and Sales Administration Coordinator
Valérie Berthelon Office Manager
Naël Mokrane Software Engineer Apprentice
Jegash Srikandarajah Production Engineer
Samuel Vergnol Full-stack Web Development Apprentice
Mariem Nayel Sales Account Manager
Antoni Homs Corbera Partner - Scientific and IP Advisor
Guilhem Velve Casquillas Co-founder and Board member

Values & Cultures

We are all passionate about improving human health and animal wellfare.

To succeed in our mission,  we have also built a strong culture based on 3 major axes :

  • Good sense of humor
  • Cooperation
  • Surpassing yourself

Humor

Cooperation

Surpassing yourself

Milestones & Highlights

Picture

2023

U.S. Patent Granted Application No. 16824071. Development of the immunocompetent liver organoids. Development of vascularized immunocompetent fully differentiated skin equivalent.

Movie

2022

Winner of the European Innovation Council EIC Transition (IDEFIX - Development of the vascularized immunocompetent breast cancer organoids).

Development of vascularized 3D adipose tissue model. French Patent Granted Application No.FR1902859

Picture

2021

Winner of 2 European Innovation Council EIC Pathfinder (PLAST_CELL - AI-based early detection of aggressive and multi-resistant breast tumor, and DeLIVERY - Impact of polypharmacy on hepatic fenestration)

Picture

2020

Winner of EuroNanoMed3 (Nano4Stroke - Development of 3D blood brain barrier model).

Cherry Biotech relocated to Paris (Montreuil), starting a strong collaboration in the same building with the company 4D Cell.

Location

2019

Pivot between Organ-on-Chip approach to standard Organ-on-Well (convert any standard multiwell into Perfused dynamic 3D culture system).

Movie

2018

Winner of the European Collaborative project EUROSTARS (IMAGINe - Development of vascularized metastatic melanoma 3D model).

Picture

2017

Finalization of the industrialization of the first scientific instrument "Cherry Temp" and scale-up production for international sales.

First result on the Artificial Intelligence (AI) R&D program based on live cell imaging.

Picture

2016

Laureate of the French I-Lab innovation competition.

Acceleration of the R&D program Organ-On-Chip (Multi-Organ-On-Chip) - Alternatives to animal testing.

Picture

2015

First international sales of the CherryTemp Beta test in Europe, Asia and United States.

Beginning of the Organ-On-Chip R&D program "Cherry360". Acceleration of the R&D program Organ-On-Chip (Multi-Organ-On-Chip) - Alternatives to animal testing.

Picture

2014

Cherry Biotech is founded in Rennes (Brittany, FR) with the mission to provide scientific instrument based on Organ-On-Chip technology, as an alternative to animal testing, to better predict drug effects on humans.

They Trust Us

speak with our expert

Speak directly with one of our experts to see how our products and services can support your research project
As part of our commercial prospecting, we may need to process your personal data. For more information, please consult our Privacy Policy